News | December 24, 2024
Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector
Exploring new opportunities within the fast-growing market of microfluidics
Exploring new opportunities within the fast-growing market of microfluidics
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Laurus Labs informs that Eight Roads Ventures and F-Prime Capital (Investors) have together invested Rs. 120 crores in Laurus Bio
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Subscribe To Our Newsletter & Stay Updated
